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Free radicalcommon neurodegenerative disorder marked by movement impairment caused
by a selective degeneration of dopaminergic neurons. The mechanism for dopaminergic neuronal
degeneration in PD is not completely clear, but it is believed that oxidative and nitrosative stress plays an
important role during the pathogenesis of PD. This notion is supported by various studies that several indices
of oxidative and nitrosative stress are increased in PD patients. In recent years, different pathways that are
known to be important for neuronal survival have been shown to be affected by oxidative and nitrosative
stress. Apart from the well-known oxidative free radicals induced protein nitration, lipid peroxidation and
DNA damage, increasing evidence also suggests that some neuroprotective pathways can be affected by nitric
oxide through S-nitrosylation. In addition, the selective dopaminergic neurodegeneration suggests that
generation of oxidative stress associated with the metabolism of dopamine is an important contributor.
Thorough understanding of how oxidative stress can contribute to the pathogenesis of PD will help formulate
potential therapy for the treatment of this neurodegenerative disorder in the future.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Oxidative and nitrosative stress has long been implicated in aging
and age-associated disorders such as neurodegenerative diseases
[1–7]. For example Parkinson's disease (PD), which is the secondmost
common neurodegenerative disorder after Alzheimer's disease (AD),
has been linked to increased levels of oxidative and nitrosative stress.
PD is characterized by a progressive loss of dopaminergic (DAergic)
neurons in the substantia nigra pars compacta (SNc) and the presence
of intracellular proteinaceous inclusion designated as Lewy bodies
(LB) [8–10]. Neurochemically, PD is marked bymitochondrial complex
I dysfunction and increased indices of oxidative stress [8–12]. In the
past decades, several pathogenic mechanisms have been proposed for
PD including oxidative and nitrosative stress, mitochondrial dysfunc-
tion, protein misfolding and aggregation, apoptosis, inﬂammatory
responses and excitotoxicity [8,13–17]. However, none of these
pathways alone has been proven to be the exact causative cytotoxic
mechanisms leading to the loss of SNc DAergic neurons in PD [18]. One
of the potential theories for neurodegeneration in PD is a “multiple hit
hypothesis”, which is analogous to carcinogenesis that is known to
involve multiple interlinking pathways and molecular events in a
sequential order [18–20]. In this review, we will focus on how
oxidative and nitrosative stress caused by accumulation of reactive
oxygen and nitrogen species (ROS and RNS) can affect different
pathways and contribute to the pathogenesis of PD.852 2358 1552.
ll rights reserved.2. Generation of ROS and RNS
Generation of ROS is an inevitable outcome of oxygen dependent
(aerobic) respiration. In eukaryotes, mitochondria generate energy
in the form of ATP from macromolecules via Krebs cycle and
electron transport chain (ETC). The high energy end products of
Krebs cycle, NADH and FADH2, donate electrons to a series of
electron carriers on ETC. This creates a proton gradient across the
inner mitochondrial membrane which drives the oxidative phos-
phorylation of ADP to ATP by the ATP synthase [1]. Electrons
donated by NADH and FADH2 will eventually reduce oxygen
molecules to water after passing through a series of electron
carriers. ETC is composed of complex I (NADH dehydrogenase),
complex II (succinate dehydrogenase), co-enzyme Q, Complex III
(cytochrome bc1 complex), cytochrome c and complex IV (cyto-
chrome c oxidase). These components reduce molecule oxygen to
H2O2 [1]. ROS are generated when electrons leak from ETC which
results in a partial reduction of molecular oxygen to superoxide.
Leakage of electrons occurs mainly at complex I, but leakage from
complex III or IV has also been reported [4,8,11,12,21]. To protect
various cellular components from oxidative damage, enzyme such as
superoxide dismutase (SOD) can metabolize superoxide to hydrogen
peroxide (H2O2) which can then be converted to H2O and O2 by
catalase (Fig. 1) [4]. These reactions are crucial for cell survival as
superoxide and H2O2 can react with other molecules to generate
additional ROS which can be extremely toxic to the cell. For
example, if H2O2 is not metabolized by catalase, it can be converted
to hydroxyl radical or hydroxyl anion in the present of ferrous iron
through the Fenton's reaction (Fig. 1) [22,23].
Fig. 1. Generation of ROS and RNS in SNc DA neuron. Leakage of electrons from the electron transport chain, especially from complex I (CI), leads to the partial reduction of molecular
oxygen to superoxide (UO2−) which is dismutated into hydrogen peroxide (H2O2) by superoxide dismutases (SOD). H2O2 is then converted into H2O and oxygen by catalase (CAT) and
peroxiredoxin (Prx). With Fe2+ as catalyst, H2O2 can also be converted to highly reactive hydroxyl radical (
UOH) through the Fenton reaction. Excessive stimulation of N-methyl-D-
aspartate receptor (NMDAR) leads to activation of neuronal nitric oxide synthase (nNOS) which produces excess amount of nitric oxide (NO). NO can react with UO2− to form the
more reactive peroxynitrite (ONOO−). ONOO− can convert to nitrogen dioxide (NO2) and the highly reactive
UOH or carbonate radical (UCO3−) when reacted with H+ or CO2.
Dopamine catabolism by monoamine oxidase (MAO) generates H2O2. Besides, oxidation of DA also produces ROS and DA quinone radical (
UDAQ) that can modify protein directly.
Under neuroinﬂammatory condition, glial cells are activated. ROS generated by NADPH oxidase (NOX) and NO produced by inducible nitric oxide synthase (iNOS) in activated glial
cells can diffuse to SNc DA neurons and contribute to both oxidative and nitrosative stress. SNc DA neurons express cyclooxygenase (COX). COX produces prostaglandin (PG) and
generates H2O2 as a byproduct.
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ROS are also generated during inﬂammation as a defense mechanism
[22]. For instance, NADPH oxidase 2 (NOX2) and other phagosomal
enzymes in phagocytes generate ROS such as superoxide and
hypochlorous acid to kill invading pathogens in the process of
inﬂammation [22]. While generation of ROS by phagocytes represents
an important defense mechanism, excessive production of ROS during
chronic inﬂammatory response might contribute signiﬁcantly to
various pathological conditions [22].
Another major contributor of oxidative stress is the metabolism of
nitric oxide (NO). NO has long been recognized as a signaling
molecule for vasodilation and neurotransmission. During signal
transduction, NO activates soluble guanylate cyclase (sGC) to generate
cGMP which acts as a second messenger to induce vasodilation [24–
27]. NO is generated by three isoforms of nitric oxide synthase (NOS):
inducible NOS (iNOS), endothelial NOS (eNOS) and neuronal NOS
(nNOS) [7]. Although NO is an important signaling molecule, it can
react with other ROS to form the highly toxic RNS [28,29]. For instance,
NO can react with superoxide anions to form peroxynitrite that can
further convert to highly toxic intermediates such as nitrogen dioxide,
carbonate and hydroxyl radicals (Fig. 1) [28,29].Another recently identiﬁed mechanism that NO can affect cell
survival is through S-nitrosylation. S-nitrosylation is a reversible
modiﬁcation of cysteine (cys) residues in proteins to form the
corresponding nitrosothiols [30–33]. A considerable number of
proteins are now found to be modiﬁed by NO through S-nitrosylation.
This modiﬁcation has been shown to regulate gene transcription,
vesicular trafﬁcking, receptor mediated signal transduction, and
apoptosis [33]. More importantly, some of the neuroprotective
proteins have been found to be modulated by S-nitrosylation, which
suggest that nitrosative stress is an important contributor to the
development of neurodegeneration [33].
3. How ROS and RNS contribute to the pathogenesis of PD
Numerous studies on postmortem brain tissues of PD patients have
suggested that ROS and RNS are involved in the degeneration of
DAergic neurons [34]. This is primary due to the observation that high
levels of lipid peroxidation, depletion of glutathione and increased
protein oxidation are common in brain tissues of PD patients. The
selective neurodegeneration in PD seems to suggest that SNc DAergic
neurons aremore vulnerable to ROS and RNS challenge, but the reason
645A.H.K. Tsang, K.K.K. Chung / Biochimica et Biophysica Acta 1792 (2009) 643–650behind this is not fully understood. One of the potential explanations
is dopamine oxidation. Dopamine (DA) is used as the neurotransmit-
ter in these neurons, and H2O2 is generated as a byproduct for the
catabolism of DA by monoamine oxidase (MAO) [23]. Besides,
dopamine oxidation can result in the formation of dopamine quinone
which can modify proteins directly [34,35]. However, many DAergic
neurons in other areas such as ventral tegmental area (VTA) in the
brain stem are not affected in PD, suggesting that the degeneration of
DAergic neurons in SNc might involve factors that are not related to
DA metabolism. Nevertheless, the mechanism of how oxidative stress
is increased in PD patients and eventually leads to degeneration of
DAergic neurons is still not conclusive [8,18].
Our recent understanding of PD pathogenic mechanism has been
greatly assisted by the discoveries of genes that are linked to familial
PD (FPD). PD is mostly sporadic but some of the PD cases have been
shown to be familial-linked. The ﬁrst FPD-linked gene that was
identiﬁed is alpha-synuclein (α-syn) [36,37]. Initially, some reserva-
tions were made on how the pathogenic mechanism of FPD was
relevant to the more common sporadic cases. This minor concern was
cleared when α-syn was found to be the major component of LB in all
PD patients [38]. The ﬁnding that mutations in α-syn can cause PD and
that this is relevant to the more common sporadic cases has opened
up a new approach to study the pathogenic mechanism of PD.
Subsequent major efforts have been made to identify additional genes
that are linked to a number of FPD cohorts [39]. So far, 4 more genes
have been linked to FPD cases and they are parkin, DJ-1, PINK1 and
LRRK2 [39]. Mutations in PINK1, DJ-1 and parkin cause early onset
autosomal recessive form of PD whereas mutations in LRRK2, like α-
syn, cause autosomal dominant PD [39]. Initial studies on these genes
suggest that they are important in mitochondrial function or in the
handling of misfolded proteins [15,18,39]. Not surprisingly, oxidative
stress is also playing important roles in affecting the normal function
of FPD-related gene products in the process of neurodegeneration. For
example, ROS and RNS are known to cause protein misfolding and
aggregation. Early studies suggest that oxidative damaged proteins
form toxic aggregates and ultimately induce neurodegeneration in PD
[40]. This notion is supported by the observation that nitrated or
oxidative damaged protein aggregates are prominent in brain tissues
from PD patients [34]. This hypothesis is best demonstrated by the
oxidative stress induced aggregation of α-syn. Under normal
physiological condition, α-syn is believed to modulate synaptic
vesicle trafﬁcking owing to its localization at the synaptic terminal
and its ability to bind to synaptic vesicles [41]. In PD, α-syn is known
to be the major component of LB [38], but the reason why α-syn is
deposited to the LB is not clear. It has been suggested that oxidative
damaged α-syn is more prone to aggregation and therefore it is
selectively deposited into the LB [42]. This suggestion is conﬁrmed by
the ﬁnding that nitrated α-syn is extensively deposited in the LB [43].
From immunoelectronmicroscopy study, it was found that nitratedα-
syn is the major ﬁlamentous building blocks of LB [43]. Nitration of α-
syn is observed in all tyrosine residues (Tyr39, Tyr125, Tyr133 and
Tyr136), and this nitration contributes to the peroxynitrite-induced
aggregation of α-syn [44]. Nitrated α-syn is more resistant to
proteolysis and prone to aggregation, and has reduced lipid binding
tendency and solubility in the cells [45]. In addition, nitrated α-syn is
more immunogenic, which might explain why increased inﬂamma-
tory response such as gliosis and T cell activation is common in PD
patients [41,46].
Apart from nitration, α-syn can undergo other oxidative modiﬁca-
tions [34]. One that has gained most attention is the addition of DA
adduct on α-syn [47]. This modiﬁcation has been shown to stabilize
the toxic α-syn protoﬁbrils, and to inhibit the protoﬁbrils from
aggregating further into less toxic insoluble ﬁbrils [48,49]. One toxic
mechanism mediated by α-syn protoﬁbrils is through permeabiliza-
tion of synaptic vesicles [49–51]. Permeabilization of synaptic vesicles
might increase intracellular DA, which could further enhance DAmodiﬁcation of α-syn and consequently, the formation of more α-syn
protoﬁbrils [51]. Besides, DA conjugated α-syn is resistant to
chaperone mediated autophagy (CMA) degradation as well as capable
of blocking other proteins from degradation via this pathway [52].
This can ultimately result in the accumulation of toxic proteins in the
cell [52]. Taken together, these studies provide potential pathogenic
mechanisms of how wild type α-syn and oxidative stress can
contribute to the neurodegenerative process in PD.
Another FPD gene that might help explain how oxidative stress can
contribute to PD is PINK1. PINK1 is a mitochondrial kinase that is
believed to be important for mitochondrial function. Various studies
have suggested that PINK1 can protect the neurons against cytotoxic
insults [39,53]. Deletion of PINK1 in Drosophila leads to muscle
degeneration and male sterility [54,55]. In mice, germline deletion of
PINK1 compromises the normal mitochondrial respiration activities in
the striatum [56]. These results suggest that PINK1 is an important
component in the protection of neurons against intrinsic and
environmental stress and is critical for the normal survival of DAergic
neurons.
Apart from PINK1, another FPD gene that is known to possess
protective function against oxidative stress is DJ-1. Various studies
suggest that DJ-1 is an antioxidant protein and a redox-sensitive
chaperone [39,53]. Overexpression of DJ-1 has been shown to protect
neurons against oxidative challenge [39,53]. Although deletion of DJ-1
in mice did not result in DAergic neuron degeneration, DJ-1 null mice
have increased oxidative stress in the mitochondria and are more
susceptible to excitotoxicity and ischemia [57–59].
4. Oxidative stress and pathways that safe guard protein
misfolding and aggregation
There are cellular pathways that protect cell against protein
misfolding and aggregation. For example, misfolded or damaged
proteins are degraded via the ubiquitin proteasomal system (UPS) or
the lysosomal degradation pathway (autophagy) [60]. In addition,
there are different chaperones such as HSP70 that help refold protein
back to their proper structure. Various studies suggest that apart from
inducing protein aggregation, oxidative stress can also impair cellular
systems that protect against misfolded or aggregated proteins.
In the endoplasmic reticulum (ER), misfolded proteins are
degraded by the ER-associated degradation (ERAD) pathway via the
UPS [61,62]. In addition, oxidative damaged proteins have been shown
to be degraded by proteasome. Involvement of UPS dysfunction in the
pathogenesis of PDwas ﬁrst suggested by the discovery of ubiquitin as
a major component of LB [63]. This is later supported by the
identiﬁcation of parkin mutations in FPD patients [64]. Parkin is an
E3 ligase in the UPS and has been shown to be a multipurpose
neuroprotectant in DAergic neurons against various toxic insults [65].
Given that parkin is an important neuroprotectant in DAergic neurons,
it was postulated that oxidative stress could affect parkin's protective
function [66]. This assumptionwas veriﬁed when parkinwas found to
be affected by two types of oxidative modiﬁcation [67–69]. It was ﬁrst
reported that parkin can be S-nitrosylated on the critical cysteine
residues within its catalytic RING domains [67,68]. S-nitrosylation of
parkin impairs its E3 ligase activity and neuroprotective function [67].
Increased S-nitrosylation of parkin is observed in brain tissues of
animal PD model and PD patients [67,68] supporting the role of
nitrosative stress in PD pathogenesis. Apart from S-nitrosylation, it
was also reported that parkin can be covalently modiﬁed by dopamine
[69]. This dopamine modiﬁcation was shown to promote parkin
aggregation and to impair its normal E3 ligase activity [69]. In the
brain tissues of PD patients, an increase in catecholamine modiﬁed
parkin was observed in the SNc [69]. These results provide a potential
explanation why DAergic neurons are more susceptible for degenera-
tion in PD. However, the reason why DAergic neurons in the SNc are
more sensitive then those in the VTA remains unclear.
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propensity of oxidized proteins to be more resistant to proteasomal
degradation possibly through the formation of aggregates [70].
Aggregated proteins are more difﬁcult to be unfolded by the 19S
regulatory complex of the proteasome. Hence, they will not be able to
enter the 20S catalytic complex for proteolytic degradation [71]. More
importantly, aggregated proteins can block the entrance of the
proteasome for other proteins thereby compromising the normal
UPS function [72].
Under normal physiological conditions, chaperones are proteins
that assist proper folding of nascent or misfolded proteins [73]. Since
neurodegenerative diseases have always been linked to protein
misfolding and aggregation, chaperones are known to be important
during the process of neurodegeneration [73]. Normally, nascent
proteins that required posttranslational modiﬁcation are targeted to
the ER for further processing. Misfolded proteins that cannot be
repaired will be exported to the cytosol for proteasomal degradation
via the ERAD pathway. Accumulation of misfolded protein that cannot
be effectively removed by ERAD leads to ER stress and activates the
unfolded protein response (UPR) [74]. This initiates the expression of
chaperones such as protein disulﬁde isomerase (PDI) and glucose-
regulated protein (GRP), inhibition of protein translation, and increased
ERAD [74]. If ER stress is not relieved, overwhelmed UPRwill eventually
elicit apoptosis [74].
A recent paper reported that PDI, a component of UPR, can be
modulated by nitrosative stress through S-nitrosylation [75]. PDI
possesses chaperone and isomerase activities that can promote
disulﬁde exchange and hence proper folding of proteins in the ER
[74]. S-nitrosylated PDI, however, shows reduced chaperone and
isomerase activities [75]. S-nitrosylation of PDI also compromises its
anti-protein aggregation ability and its protective function against
various cytotoxic insults [75]. Apart from PDI, cytosolic chaperones
such as HSP70 and HSP90 have also been shown to be S-nitrosylated
by NO [76]. Although the functional consequence of HSP70 modiﬁca-
tion by NO is unknown, S-nitrosylation of HSP90 abolishes its ATPase
activity, which is required for its chaperone function [77].
5. Oxidative stress and mitochondrial dysfunction
Mitochondrial dysfunction has longbeen considered as an important
mechanism in the pathogenesis of PD. This is supported by pathological
studies that complex I dysfunction is commonly observed in PD patients
[11]. An important ﬁnding that links mitochondrial dysfunction and PD
comes froma group of drug abuserwhich developed PD symptoms after
an accidental exposure of 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine
(MPTP) in 1980s [78]. The toxicity of MPTP is attributed to its ability to
cross the blood brain barrier and be metabolized by MAO-B to (1-
methyl-4-phenylpyridinium) MPP+ [79]. The MPP+ is selectively
uptaken by DAergic neurons via DA transporter (DAT). Because MPP+
is a mitochondrial complex I inhibitor, this causes the generation of
excessive amount of free radicals which lead to the demise of DA
neurons [15]. In fact, because of the speciﬁcity of the neurotoxicity effect
of MPTP on DA neurons, it is now widely used in animal models to
recapitulate PD conditions.
Apart from being the site of ROS generation, mitochondrial
function can also be affected by ROS. For example, studies have
found that oxidative damage such as S-nitrosylation of complex I can
inhibit its normal activity [80]. Inhibition of complex I can lead to
leakage of electrons from ETC and partial reduction of molecular
oxygen to superoxide that can subsequently convert to other ROS [1].
Given that complex I activity is redox sensitive, the feedforward
mechanismmight represent an important mechanism of neuronal cell
death [11,12]. Apart from complex I, several enzymes in the Krebs cycle
such as alpha-ketoglutarate dehydrogenase, succinate dehydrogenase
and isocitrate dehydrogenase can also be inactivated by oxidation [2].
Reduced activity of these enzymes together with the complex Idysfunction can contribute to reduced ATP biosynthesis. Reduced ATP
generation may then inhibit ATP dependent cytoprotective pathways
such as 26S proteasomal mediated protein degradation, chaperone
activities, and calcium pumps that regulate cellular calcium levels in
the mitochondria and ER [12,81]. Low ATP levels will also affect the
transcriptional and translational processes that produce enzymes
such as SOD and catalase to cope with increased oxidative challenge
[12,81]. Taken together, the survival of neurons is compromised under
these unfavorable conditions.
6. Oxidative stress and apoptosis
Apoptosis has long been implicated in the process of neurodegen-
eration in PD pathogenesis [13]. For example, activation of caspase 3
has been reported in the brain tissues of PD patients [82], whereas
overexpression of X-linked inhibitor of apoptosis in rat brain has been
shown to be neuroprotective against MPTP treatment [83]. Not
surprisingly, several components of apoptosis are redox sensitive
and are substrates for post-translational oxidative modiﬁcation [84].
For example, it is known that S-nitrosylation can modulate apoptosis
by acting on a number of important apoptotic proteins [85]. Caspase 3
is one of the components that initiate apoptosis. Under normal
physiological condition, caspase 3 is constitutively S-nitrosylated
which prevents it from initiating apoptosis [86,87]. However, upon
stimulation by apoptotic insults such as the activation of Fas, caspase 3
is selectively denitrosylated and thus can initiate the process of
apoptosis [87]. In contrast, thioredoxin stimulates S-nitrosylation of
caspase 3, and this acts as a housekeeping mechanism for the
prevention of accidental initiation of apoptosis [88].
Two additional proteins with anti-apoptotic function, p21 Ras and
Bcl2, have been shown to be modiﬁed by NO through S-nitrosylation
[89–91]. S-nitrosylation of p21 Ras leads to its activation into the GTP-
bound form and facilitates its function in the prosurvival downstream
signaling [92]. In fact, this modiﬁcation has recently been implicated
in tumorigenesis [93]. Another anti-apoptotic protein, Bcl2, mainly
antagonizes the proapoptotic members of Bcl2 family (BAX, BAK) and
prevents their induction of outer mitochondrial membrane permea-
bilization [94]. S-nitrosylation of Bcl2 reduces its degradation by the
proteasome and thus inhibits apoptosis [94].
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an
enzyme involved in the process of glycolysis. Previous studies
found that GAPDH is translocated to the nucleus during the process
of cell death, but the exact mechanism and function of this
translocation were not clear [95]. Recent studies suggest that
GAPDH translocation to the nucleus is mediated by S-nitrosylation
[96]. GAPDH is S-nitrosylated at cys 150 and this modiﬁcation
enables its interaction with Siah1, an E3 ubiquitin ligase that is
known to be involved in the process of apoptosis [97]. Since Siah1
contains a nuclear localization signaling sequence, the S-nitrosylation
dependent binding of GAPDH to Siah1 enables translocation of the
complex to the nucleus [96]. In the nucleus, GAPDH protects Siah1
from proteasomal degradation so that Siah1 can facilitate the
degradation of nuclear proteins to initiate apoptosis [96]. In addition,
GAPDH itself in the nucleus can elicit several cytotoxic mechanisms
such as binding to DNA and tRNA, self-aggregation, and alternation of
nuclear protein functionality [98–100]. This NO dependent nuclear
translocation of GAPDH–Siah1 complex has been shown to occur in
the MPTP animal model of PD [101]. In addition, the GAPDH–Siah1
complex provides a molecular mechanism of how deprenyl (Selegi-
line) can be neuroprotective against MPTP induced toxicity [101].
Deprenyl is known to be a MAO-B inhibitor and it can protect mice
from MPTP-induced toxicity by preventing the conversion of MPTP to
MPP+. However, more recent ﬁndings suggest that deprenyl confers
neuroprotection through the disruption of GAPDH S-nitrosylation,
thereby preventing the formation of the GAPDH–Siah1 cell death
inducing complex [101].
Fig. 2. Pathogenic pathways that contribute to the SNc neuronal cell death. Dopamine
metabolism, inﬂammation and excitotoxicity contribute to the generation of excessive
amount of ROS and RNS. Dysfunctions of proteolytic system andmitochondria represent
twomajor pathogenic pathways contributing to SNc neuronal cell death. Mitochondrial
dysfunction is simultaneously a cause and a consequence of oxidative stress.
Deregulation of mitochondrial respiration leads to generation of ROS and thus
contributes to oxidative stress. In return, oxidative and nitrosative stress deteriorates
mitochondrial function which contributes to a pathogenic feedforward cycle.
Mitochondrial dysfunction results in a compromised ATP biogenesis which hinders
energy dependent stress coping mechanisms of neurons such as ATP dependent
degradation of misfolded proteins by the UPS. Besides, mitochondrial dysfunction can
directly contribute to neuronal cell death by triggering apoptotic pathways. Proteolytic
system acts as a safeguard system to eliminate misfolded or aggregated proteins which
otherwise are toxic to SNc neurons. However, excessive amount of oxidatively damaged
proteins can overwhelm the proteolytic system and hence results in the further
accumulation of misfolded or aggregated proteins that can compromise the survival of
SNc DA neurons. Besides, ROS and RNS can directly affect the performance of proteolytic
system by the modiﬁcation of speciﬁc components in the system.
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Overstimulation of N-methyl-D-aspartate receptor (NMDAR) by its
ligand glutamate results in excitotoxicity [6]. NMDAR is a ligand-gated
Ca2+ channel. Overstimulation of NMDAR results in the inﬂux of
extracellular Ca2+ which can elicit a wide array of physiological and
pathological responses. For example, at the post-synaptic terminal,
nNOS is linked to the NMDAR via the PDZ domain [102]. During the
activation of NMDAR, the increased inﬂux of Ca2+ leads to the
activation of nNOS in a calmodulin-dependent manner [102].
Activated nNOS produces NO and this can react with other ROS to
form the highly toxic peroxynitrite. Peroxynitrite can induce cellular
damages through protein nitration, lipid peroxidation and DNA
fragmentation [28]. This pathological mechanism is supported by
studies using the MPTP mouse model of PD. When MPTP is
administrated to the animal, MPTP is metabolized to MPP+ by MAO
[103]. MPP+ inhibits complex I of mitochondria and this leads to
excessive production of ROS. ROS can then react with NO to form the
highly toxic peroxynitrite which can ultimately contribute to DAergic
neuronal degeneration [104,105]. This pathogenic mechanism has
been veriﬁed in iNOS and nNOS knock out mice in which these
animals are resistant to MPTP induced toxicity [106,107].
Another pathway that has been linked to excitotoxicity and
pathogenesis of PD is the activation of cyclin-dependent kinase 5
(Cdk5) [108,109]. Cdk5 is a serine/threonine kinase that requires
activating partners, p35 and p39 [108,109]. The kinase activity of Cdk5
is known to regulate a number of neuronal functions such as
development, migration, synaptic plasticity, axon guidance and
neuronal survival [110]. Dysregulation of Cdk5 activity has been
implicated in cognitive dysfunction and neurodegenerative disorders
[108,109]. For example, over-activation of NMDAR has been shown to
induce cleavage of p35 to p25, which is a stronger Cdk5 activator
[111,112]. This over-activation of Cdk5 has been shown to impair
neuronal survival [111,112]. Recently, Cdk5 over-activation has been
linked to the pathogenesis of PD [113,114]. Over-activation of Cdk5 is
mediated by calpains through the cleavage of p35 to p25 [111,112]. In
the mouse MPTP model of PD, increased Cdk5 activity was observed
and it was found to bemediated by the cleavage of p35 to p25 through
the activation of calpains [113,114]. The downstream targets of
activated Cdk5 include the transcription factor myocyte enhancer
factor 2 (MEF2) and an antioxidative stress enzyme peroxiredoxin 2
(Prx2) [113,114]. In the mouse MPTP model of PD, increased ROS lead
to activation of Cdk5 which phosphorylates MEF2 and Prx2 [113,114].
MEF2 is an important transcriptional activator of prosurvival genes
[115], whereas Prx2 protects cell against oxidative stress by breaking
down H2O2 to H2O and O2 [15]. Phosphorylation of MEF2 and Prx2 by
activated Cdk5 attenuate their normal prosurvival functions [113,114].
Interestingly, another recent study on Prx2 has revealed that S-
nitrosylation can also attenuate Prx2′s catalytic activity which in turn
reduces cell viability {Fang, 2007 #45}.
8. Oxidative stress and genetic models of PD
The identiﬁcation of FPD linked gene products provides an exciting
opportunity for the generation of genetic models of PD. The ﬁrst
genetic model of PD is the overexpression of wild type α-syn in
neurons [116]. Overexpression of α-syn results in the accumulation of
α-syn and ubiquitin positive immunoreactive protein aggregates in
neurons in association with the loss of DAergic terminals in the
striatum [116]. The oxidative stress induced protein aggregation
hypothesis as discussed suggests thatα-syn is crucial in the process of
oxidative stress induced degeneration of SNc neurons. This turns out
to be valid as α-syn null mice are resistant to MPTP induced toxicity
[117]. In other FPD linked genetic models, both PINK1 and DJ-1 null
mice have increased levels of oxidative stress in the tissues [56,58]. In
DJ-1 null mice, these animals are more sensitive to MPTP inducedtoxicity and ischemia in relation to increased levels of oxidative stress
[57,118]. It will be interesting to know if PINK1 null mice will exhibit
the similar sensitivity to MPTP induced toxicity as in DJ-1 null mice.
Several reports have shown that deletion of parkin in mice does not
induce degeneration of DAergic neurons in the SNc [119–121]. Instead
degeneration of tyrosine hydroxlase positive neurons in the Locus
coeruleus was found in these mice [120]. Interestingly, treatment of
parkin null mice with MPTP does not result in an exacerbation of SNc
DAergic neuronal degeneration [120,122].
9. Concluding remarks
Mitochondrial dysfunction and protein aggregation are two of the
widely accepted pathogenic pathways contributing to PD. Other
pathways such as apoptosis, excitotoxicity, disruption of calcium
homeostasis, and inﬂammation have also been implicated in PD
(Fig. 2). Redox imbalance caused by accumulation of excessive ROS
and RNS is another important factor that modulates these pathways
and contributes to PD pathogenesis (Fig. 2). Recent studies suggest
that NO can affect different neuroprotective pathways through S-
nitrosylation. Similar to cancer, multiple hits might be a prerequisite
for the onset of PD. Since oxidative and nitrosative stress plays an
important role in PD development, countering ROS and RNS-mediated
toxicity would be an essential and integral part of PD therapy. Taken
together, better understanding of the distinct chemical properties of
different species of ROS and RNS and how they exert their cytotoxic
effect will be needed to design a better treatment for PD in the future.
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